Introduction {#sec1_1}
============

Hepatitis E virus (HEV) is a non-enveloped, single-stranded positive-sense RNA virus of approximately 7.2 kb \[[@B1]\]. HEV infection is transmitted primarily through the fecal-oral route \[[@B1],[@B2]\]. HEV infection may lead to acute hepatitis, including acute liver failure \[[@B3]\], and chronic hepatitis in organ transplant recipients \[[@B4]\]. HEV infection is recognized as a serious health problem in developing and in developed countries \[[@B1],[@B2],[@B3],[@B4],[@B5],[@B6]\].

In Japan, 3.4% of qualified blood donors were positive for immunoglobulin (Ig)G anti-HEV antibodies \[[@B7]\]. Our previous study showed that 23% of the indigenous Japanese population, including individuals over 50 years of age \[[@B8]\], were positive for IgG anti-HEV antibodies. This suggests that Japanese subjects are susceptible to HEV infection and demonstrates the importance of controlling and investigating HEV infection due to the lack of availability of an HEV vaccine in Japan. In 2011, IgA anti-HEV antibody tests were available for the diagnosis of HEV by the Japanese national health insurance system \[[@B9]\].

In patients with rheumatoid arthritis (RA), acute liver injury associated with autoimmune hepatitis and drug-induced liver injury (DILI), reactivation of hepatitis B virus (HBV), and liver dysfunction caused by other reasons are occasionally observed \[[@B10],[@B11]\]. Here, we report 5 patients who were recently identified to have HEV infection, 3 of whom were also diagnosed with RA.

Case Report {#sec1_2}
===========

Five cases of HEV infection were observed in our hospital between January 2014 and April 2015. HEV infection was diagnosed by positivity for IgA anti-HEV antibody \[[@B9]\]. The clinical features of the 5 patients in the present study are briefly described in table [1](#T1){ref-type="table"}. Case 5 visited our hospital approximately 150 days after onset. All patients were over 50 years old, and 4 of them were female patients. Three cases visited a hospital for their RA, and they took several types of medicine to treat the RA. Cases 2 and 4 drank alcohol (40 and 20 g daily, respectively). Autoantibodies were positive in 3 cases (cases 1, 2, and 5). The clinical courses and laboratory data from the first visit are shown in figure [1](#F1){ref-type="fig"} and table [2](#T2){ref-type="table"}, respectively.

Case 1 {#sec2_1}
------

A 64-year-old female who was diagnosed with RA 9 years ago and who received treatment in another hospital was referred to our hospital with general fatigue and liver dysfunction (table [1](#T1){ref-type="table"}; fig. [1a](#F1){ref-type="fig"}). Laboratory data on the first visit to our hospital showed an improved liver function test (table [2a](#T2){ref-type="table"}). Her height and body weight were 147 cm and 44 kg, respectively. She was positive for HEV genotype 3 RNA and IgA anti-HEV antibody (fig. [1a](#F1){ref-type="fig"}). She was also positive for anti-mitochondrial antibody, and a liver biopsy showed Scheuer stage I of primary biliary cirrhosis (PBC) (fig. [2a, b](#F2){ref-type="fig"}). We ultimately diagnosed her as having HEV infection and PBC, although we initially doubted DILI.

Case 2 {#sec2_2}
------

A 59-year-old male with a diagnosis of alcoholic liver disease was referred to our hospital with general fatigue and marked liver dysfunction (tables [1](#T1){ref-type="table"}, [2b](#T2){ref-type="table"}; fig. [1b](#F1){ref-type="fig"}). His height and body weight were 176 cm and 69 kg, respectively. He was positive for HEV genotype 3 RNA and IgA anti-HEV antibody (fig. [1b](#F1){ref-type="fig"}). We diagnosed him as having HEV infection. After admission to our hospital, he was given bed rest and peripheral parenteral nutrition, and his condition improved. This patient had consumed deer meat approximately 1 month before admission.

Case 3 {#sec2_3}
------

A 74-year-old female who was diagnosed as having RA 20 years ago and was treated in a different hospital was referred to our hospital with general fatigue and liver dysfunction (tables [1](#T1){ref-type="table"}, [2c](#T2){ref-type="table"}; fig. [1c](#F1){ref-type="fig"}). Her height and body weight were 154 cm and 54 kg, respectively. Because she was treated with tofacitinib only 2 months previously, we initially doubted that DILI was caused by this drug. However, she was positive for HEV genotype 3 RNA and IgA anti-HEV antibody (fig. [1c](#F1){ref-type="fig"}). We diagnosed her as having HEV infection.

Case 4 {#sec2_4}
------

A 52-year-old female who was diagnosed with RA 4 years ago and whose RA was treated in another hospital was referred to our hospital with general fatigue and liver dysfunction (tables [1](#T1){ref-type="table"}, [2d](#T2){ref-type="table"}; fig. [1d](#F1){ref-type="fig"}). Her height and body weight were 152 cm and 50 kg, respectively. She was positive for HEV genotype 3 RNA and IgA anti-HEV antibody (fig. [1d](#F1){ref-type="fig"}). We diagnosed her as having HEV infection. After admission to our hospital, she was given bed rest and peripheral parenteral nutrition, and her condition improved. A liver biopsy confirmed acute hepatitis (fig. [2c, d](#F2){ref-type="fig"}).

Case 5 {#sec2_5}
------

A 77-year-old female who was diagnosed with HEV infection based on positivity for IgA anti-HEV antibody approximately 150 days before admission to our hospital was referred to our hospital with general fatigue and liver dysfunction (tables [1](#T1){ref-type="table"}, [2e](#T2){ref-type="table"}; fig. [1e](#F1){ref-type="fig"}). Her height and body weight were 144 cm and 50 kg, respectively. She was positive for antinuclear antibody, and her IgG was elevated. A liver biopsy showed typical characteristics of autoimmune hepatitis (fig. [2e--g](#F2){ref-type="fig"}). We began corticosteroid therapy, and her liver tests improved; however, her positivity for IgA anti-HEV persisted 9 months after onset. Upon admission to our hospital, although HEV RNA was negative, we diagnosed her as having HEV infection according to the changes of titers of anti-HEV antibodies (fig. [1e](#F1){ref-type="fig"}). An updated (1999) scoring system for the diagnosis of autoimmune hepatitis \[[@B12]\] indicated probable autoimmune hepatitis (score: 16) because viral hepatitis by HEV was not completely ruled out on this score system.

Discussion {#sec1_3}
==========

In the current study, we presented 5 cases with HEV infection. The mean age of these patients was 65 ± 11 years, 4 patients were female, and 3 had RA. Two patients were over 65 years of age, and 1 of these 2 patients was over 65 years old and had RA. Only 1 male patient without RA reported consumption of deer meet before onset. In the other 4 patients, the infectious sources of HEV were unknown.

Pischke et al. \[[@B13]\] reported that patients with autoimmune hepatitis, but not RA or HBV/HCV patients, are more likely to test positive for anti-HEV. They reported that only 4 of 114 (3.5%) RA patients were positive for HEV-specific antibodies, similar to healthy individuals \[11 of 537 (2.0%)\]. However, we found that 3 of 5 patients with HEV infection had RA. The present study suggests that it is important to rule out HEV infection in RA patients with liver dysfunction.

Although an initial diagnosis of HEV infection was made based on the positivity for IgA anti-HEV antibody in case 5, she was also diagnosed as having autoimmune hepatitis based on a subsequent liver biopsy (fig. [2e](#F2){ref-type="fig"}). Although a corticosteroid was administered and her liver dysfunction improved, positivity for IgA anti-HEV antibody persisted for 9 months after onset. It is well known that autoimmune hepatitis rarely follows acute viral hepatitis \[[@B14]\]. Inagaki et al. \[[@B15]\] reported that a 65-year-old female with HEV RNA was diagnosed as having probable autoimmune hepatitis and was successfully treated with prednisolone. Nagasaki et al. \[[@B16]\] also recommended that HEV infection should be ruled out in the cases with acute cryptogenic hepatitis, including autoimmune hepatitis. Three of the cases described in the present study were positive for autoantibodies. Careful attention should be given to these features \[[@B17]\]. Together, HEV infection could trigger autoimmune hepatitis in some cases.

Recently, reports about HBV reactivation in RA patients treated with newer biological drugs like tocilizumab and abatacept have been increasing \[[@B18]\]. A remarkably high incidence of tuberculosis in RA patients treated with TNF-α antagonists has been reported \[[@B19]\]. In the present study, 3 patients with RA were well controlled and had stable activity of RA. Of interest, case 3 took tofacitinib. Further studies will be needed.

RA patients with liver dysfunction are treated with several medications, and DILI should also be ruled out (table [1](#T1){ref-type="table"}), as well as viral hepatitis. In conclusion, due, in part, to the availability of the IgA anti-HEV antibody, we have recently diagnosed 5 cases as being positive for HEV. In RA patients with liver dysfunction, HEV infection should also be ruled out using the IgA anti-HEV antibody, because these patients include older patients. Further studies regarding the association between HEV and autoimmune hepatitis are needed. The present study also showed that HEV infection is an important emerging health concern.
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![Clinical course of 5 patients with HEV infection in the present study. **a** Case 1. **b** Case 2. **c** Case 3. **d** Case 4. **e** Case 5. Cases 1, 3, and 4 visited a hospital for their RA. Cases 1-4 were positive for HEV RNA at least at one time point. Samples from cases 2-4 contain HEV genotype 3b determined based on an analysis of the 412-nt ORF2 sequence \[[@B20]\]. As the HEV RNA level was low titer in case 1, the sample from case 1 contains HEV genotype 3 determined based on an analysis of the 97-nt ORF2/3 sequence \[[@B20]\]. In case 5, we did not detect HEV RNA, but we diagnosed this case as HEV infection according to changes in titers of anti-HEV antibodies. AST = Aspartate transaminase; ALT = alanine transaminase; T-BIL = total bilirubin; UDCA = ursodeoxycholic acid; ANA = anti-nuclear antibody; PT = prothrombin time; PSL = prednisolone.](crg-0009-0317-g01){#F1}

![Liver biopsy findings in cases 1, 4, and 5. In case 1, the hepatic architecture was preserved (**a** HE, ×40), and findings were compatible to Scheuer stage I of PBC (**b** HE, ×100). In case 4, the hepatic architecture was preserved, and marked inflammation in periportal areas (**c** HE, ×100) and centrilobular necrosis (**d** HE, ×100) were observed, indicating acute hepatitis. In case 5, a liver biopsy showed a partly preserved hepatic architecture but no cirrhosis (**e** HE, ×40). Marked inflammation including rosette formation in the periportal area (**f** HE, ×100) and plasma cell infiltration (**g** HE, ×100) were observed, suggesting autoimmune hepatitis.](crg-0009-0317-g02){#F2}

###### 

Clinical features of 5 patients with HEV infection

                                                    Case 1                                                                                                                    Case 2                 Case 3                                                                                                                                            Case 4                                                                                                                               Case 5
  ------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------
  Age, years/gender                                 64/female                                                                                                                 59/male                74/female                                                                                                                                         52/female                                                                                                                            77/female
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Duration, days[^1^](#T1F1){ref-type="table-fn"}   19                                                                                                                        1                      7                                                                                                                                                 9                                                                                                                                    ∼150
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Underlying diseases                               RA                                                                                                                        ALD                    RA                                                                                                                                                RA                                                                                                                                   hypertension
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Symptom(s)                                        fatigue                                                                                                                   fever, fatigue         fatigue                                                                                                                                           epigastric discomfort                                                                                                                fatigue
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Max. AST, IU/l                                    202                                                                                                                       1,953                  842                                                                                                                                               813                                                                                                                                  793
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Max. ALT, IU/l                                    527                                                                                                                       1,944                  753                                                                                                                                               973                                                                                                                                  850
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Max. total bilirubin, mg/dl                       0.6                                                                                                                       5.4                    0.7                                                                                                                                               1.1                                                                                                                                  1.7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Min. PT, %                                        126                                                                                                                       100                    114                                                                                                                                               84                                                                                                                                   56
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Source of infection                               unknown                                                                                                                   deer meat              unknown                                                                                                                                           unknown                                                                                                                              unknown
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  ANA, -fold                                        80                                                                                                                        160                    80                                                                                                                                                40                                                                                                                                   320
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  ASMA, -fold/AMA M2                                80/14.6                                                                                                                   neg./neg.              neg./neg.                                                                                                                                         neg./neg.                                                                                                                            neg./neg.
  Medicine before onset                             bucillamine, loxoprofen, methotrexate, folic acid, alendronate, eldecalcitol, rabeprazole sodium, magnesium oxide, UDCA   acetylsalicylic acid   tofacitinib, prednisolone, loxoprofen, salazosulfa-pyridine, eldecalcitol, tocopherol nicotinate, methylcobalamin, teprenone, limaprost alfadex   methotrexate, triamcinolone, folic acid, pregabalin, roxatidine acetate hydrochloride, neurotropin, amoxapine, sulpiride, etizolam   nifedipine, candesartan cilexetil, doxazosin, famotidine, rebamipide, UDCA

ALD = Alcoholic liver disease; AST = aspartate transaminase; ALT = alanine transaminase; Max. = maximum; Min. = minimum; PT = prothrombin time; ANA = anti-nuclear antibody; ASMA = anti-smooth muscle antibody; AMA = anti-mitochondrial antibody; neg. = negative; UDCA = ursodeoxycholic acid.

Duration between onset and visit to the hospital.

###### 

Laboratory data for 5 patients with HEV infection on their first visit

  Category         Units        Category      Units             Category   Units
  ---------------- ------------ ------------- ----------------- ---------- ------------
  **a** *Case 1*                                                           
  AST              22 IU/l      WBC           6,600/mm^3^       IgM HA     (--)
  ALT              46 IU/l      RBC           419×10^4^/mm^3^   IgM HBc    (--)
  G-GTP            35 IU/l      Hb            13.2 g/dl         HBsAg      (--)
  ALP              185 IU/l     Hct           38.5%             HBsAb      (--)
  LDH              172 IU/l     Platelets     301×10^3^/mm^3^   HBcAb      (--)
  TP               7.5 g/dl     Eosinophils   1.5%              HBV DNA    (--)
  ALB              3.9 g/dl     PT%           126%              HCV Ab     (--)
  T. Bil           0.5 mg/dl    PT-INR        0.91              HCV RNA    (--)
  D. Bil           0.1 mg/dl    ESR           25 mm/h           IgA HEV    (+)
  T. CHO           187 mg/dl    HbA1C         5.0%              ANA        ×80
  UA               5.0 mg/dl    IgG           1,580 mg/dl       ASMA       ×80
  UN               13 mg/dl     IgM           337 mg/dl         AMA M2     14.6 (+)
  Cre              0.46 mg/dl   IgA           299 mg/dl         aLKM1      (--)
  CRP              0.1 mg/dl    TSH           1.086 μIU/ml      AFP        3.2 ng/ml
                                                                           
  **b** *Case 2*                                                           
                                                                           
  AST              1,953 IU/l   WBC           3,900/mm^3^       IgM HA     (--)
  ALT              1,944 IU/l   RBC           473×10^4^/mm^3^   IgM HBc    (--)
  G-GTP            401 IU/l     Hb            14.6 g/dl         HBsAg      (--)
  ALP              710 IU/l     Hct           43.4%             HBsAb      (--)
  LDH              1,293 IU/l   Platelets     127×10^3^/mm^3^   HBcAb      (--)
  TP               7.4 g/dl     PT%           111%              HBV DNA    (--)
  ALB              3.9 g/dl     PT-INR        1.01              HCV Ab     (--)
  T. Bil           4.5 mg/dl    ESR           35 mm/h           HCV RNA    (--)
  D. Bil           3.2 mg/dl    HbA1C         5.4%              IgA HEV    (+)
  T. CHO           197 mg/dl    IgG           1,928 mg/dl       ANA        ×160
  UA               5.6 mg/dl    IgM           259 mg/dl         ASMA       (--)
  UN               20 mg/dl     IgA           259 mg/dl         AMA        (--)
  Cre              0.79 mg/dl   TSH           3.604 μIU/ml      HIV        (--)
  CRP              2.2 mg/dl    HA            71 ng/ml          AFP        26.5 ng/ml
                                                                           
  **c** *Case 3*                                                           
  AST              262 IU/l     WBC           12,800/mm^3^      IgM HA     (--)
  ALT              444 IU/l     RBC           386×10^4^/mm^3^   IgM HBc    (--)
  G-GTP            68 IU/l      Hb            12.2 g/dl         HBsAg      (--)
  ALP              229 IU/l     Hct           36.9%             HBV DNA    (--)
  LDH              310 IU/l     Platelets     286×10^3^/mm^3^   HCV Ab     (--)
  TP               7.4 g/dl     Eosinophils   0.2%              HCV RNA    (--)
  ALB              4.1 g/dl     PT%           114%              IgA HEV    (+)
  T. Bil           0.6 mg/dl    PT-INR        1.02              ANA        ×80
  D. Bil           0.1 mg/dl    ESR           27 mm/h           ASMA       (--)
  T. CHO           200 mg/dl    HbA1C         5.4%              AMA        (--)
  UA               6.4 mg/dl    IgG           1,551 mg/dl                  
  UN               19 mg/dl     IgM           187 mg/dl                    
  Cre              0.68 mg/dl   IgA           145 mg/dl                    
  CRP              3.4 mg/dl    TSH           1.017 μIU/ml                 
                                                                           
  **d** *Case 4*                                                           
  AST              565 IU/l     WBC           4,200/mm^3^       IgM HA     (--)
  ALT              973 IU/l     RBC           411×10^4^/mm^3^   IgM HBc    (--)
  G-GTP            506 IU/l     Hb            14.1 g/dl         HBsAg      (--)
  ALP              1,214 IU/l   Hct           41.0%             HBV DNA    (--)
  LDH              374 IU/l     Platelets     327×10^3^/mm^3^   HCV Ab     (--)
  TP               7.9 g/dl     Eosinophils   0.7%              HCV RNA    (--)
  ALB              4.2 g/dl     PT%           108%              IgA HEV    (+)
  T. Bil           4.3 mg/dl    PT-INR        1.00              ANA        ×40 (--)
  D. Bil           3.3 mg/dl    ESR           22 mm/h           ASMA       (--)
  T. CHO           161 mg/dl    HbA1C         4.9%              AMA M2     1.6 (--)
  UA               3.7 mg/dl    IgG           1,552 mg/dl                  
  UN               8 mg/dl      IgM           211 mg/dl                    
  Cre              0.53 mg/dl   IgA           178 mg/dl                    
  CRP              1.1 mg/dl    TSH           0.743 μIU/ml                 
                                                                           
  **e** *Case 5*                                                           
  AST              209 IU/l     WBC           9,200/mm^3^       IgM HA     (--)
  ALT              227 IU/l     RBC           381×10^4^/mm^3^   IgM HBc    (--)
  G-GTP            56 IU/l      Hb            12.5 g/dl         HBsAg      (--)
  ALP              723 IU/l     Hct           37.5%             HBV DNA    (--)
  LDH              338 IU/l     Platelets     132×10^3^/mm^3^   HCV Ab     (--)
  TP               7.1 g/dl     Eosinophils   0.5%              HCV RNA    (--)
  ALB              2.5 g/dl     PT%           60%               IgA HEV    (+)
  T. Bil           1.5 mg/dl    PT-INR        1.27              HEV RNA    (--)
  D. Bil           0.4 mg/dl    ESR           20 mm/h           IgG HEV    (+)
  T. CHO           146 mg/dl    HbA1C         4.9%              ANA        ×320 (+)
  UA               5.1 mg/dl    IgG           2,777 mg/dl       ASMA       (--)
  UN               10 mg/dl     IgM           163 mg/dl         AMA        (--)
  Cre              0.54 mg/dl   IgA           560 mg/dl         ACE        31.9
  CRP              0.8 mg/dl    TSH           1.151 μIU/ml      NH3        82 μg/ml
